Evidence reviewed: 8 November 2026. Hepatitis B virus (HBV) and hepatitis C virus (HCV) can cause acute or chronic liver infection, inflammation, cirrhosis and hepatocellular carcinoma (liver cancer). They share some routes of blood exposure but differ greatly in virology, vaccination and treatment. A safe and effective hepatitis B vaccine exists, and long-term antivirals can suppress chronic HBV, but they usually do not eliminate every reservoir of the virus. For hepatitis C, direct-acting antiviral (DAA) medicines cure more than 95% of patients with appropriate treatment, often in 8–12 weeks, yet no effective HCV vaccine exists. Important references include WHO’s 2024 HBV guideline, the 2025 AASLD/IDSA HBV update and 2026 HCV information [1–5].
Hepatitis B versus hepatitis C: main differences
| Feature | Hepatitis B (HBV) | Hepatitis C (HCV) |
|---|---|---|
| Virus type | Partially double-stranded DNA virus; produces nuclear cccDNA in hepatocytes. | Positive-sense RNA virus; replicates predominantly in cytoplasmic compartments. |
| Transmission | Blood, sex, perinatal transmission and certain body-fluid exposures. | Primarily blood-to-blood exposure; sexual and perinatal transmission are possible but generally less efficient. |
| Vaccine | Yes; routine infant and risk-based adult immunization. | No effective vaccine currently available. |
| Chronic treatment | Suppression using tenofovir or entecavir when indicated, often long term. | Oral direct-acting antiviral combinations, often 8–12 weeks. |
| Usual treatment goal | Reduce HBV DNA, liver injury, cirrhosis and cancer risk; functional cure is uncommon. | Sustained virologic response (SVR12), generally indicating virologic cure. |
| Reinfection/reactivation | HBV may reactivate during immunosuppression; requires careful risk assessment. | HCV can recur through reinfection after cure; HBV reactivation is a concern during HCV DAA treatment in coinfected people. |
How is hepatitis B transmitted?
HBV can spread through unprotected sexual contact, shared injection equipment, blood exposure in healthcare or other procedures, and from an infected pregnant person to the infant during childbirth. It can also spread through shared razors or toothbrushes if infected blood is present. Because HBV is highly infectious, vaccination and infection-control precautions are essential [1,2].
HBV is not usually spread by hugging, sharing meals, handshakes, coughing or ordinary social contact. Routine food preparation and social activities do not justify excluding someone from school or work because of chronic HBV infection.
How is hepatitis C transmitted?
HCV spreads primarily through exposure to infected blood, particularly shared injection equipment, unsafe healthcare injections or procedures, and inadequately screened blood products. Sexual transmission can occur, especially with blood exposure and in some higher-risk sexual networks. Transmission during pregnancy or birth is also possible [3,5].
HCV is not spread by casual contact, hugging, eating together or sharing drinking water. Tattooing and piercing are generally safer when appropriate sterilization and single-use equipment are used. Prevention efforts should reduce exposure and stigma rather than imply that every person with hepatitis C has used injected drugs.
What symptoms can hepatitis cause?
Many people with HBV or HCV have no early symptoms. Acute hepatitis may cause:
- Fatigue, nausea, reduced appetite or abdominal discomfort.
- Dark urine, pale stools or yellowing of eyes/skin (jaundice).
- Fever, joint pain or generalized malaise.
- Occasionally severe liver dysfunction with confusion, unusual bleeding or rapidly worsening jaundice.
Chronic infection can be asymptomatic for years while inflammation or fibrosis develops. Normal or mildly elevated liver enzymes do not guarantee that chronic infection is harmless. Testing and fibrosis assessment matter even when someone feels well [1–5].
When does hepatitis become an emergency?
New confusion, severe drowsiness, spontaneous bleeding, rapidly progressive jaundice, severe dehydration or substantial abdominal swelling may indicate serious liver disease and require urgent hospital evaluation. People with cirrhosis should obtain prompt care for vomiting blood, black stools, fever with ascites or altered mental status.
Acute liver failure is uncommon, but potentially life-threatening. Do not attempt to treat suspected severe hepatitis with herbal “liver cleanses,” alcohol or extra acetaminophen/paracetamol.
How is hepatitis B diagnosed? The CDC triple panel
The CDC recommends one-time screening of all adults using an initial triple panel of HBsAg, anti-HBs and total anti-HBc, with further tests selected according to the pattern [2,6]. These markers answer different questions:
| Test | Meaning |
|---|---|
| HBsAg | Presence generally indicates current HBV infection (acute or chronic). |
| Anti-HBs | Suggests immunity from vaccination or recovery when interpreted with other markers. |
| Total anti-HBc | Evidence of natural exposure to HBV; generally not positive after vaccination alone. |
| IgM anti-HBc | Useful when acute or recent HBV is suspected, with limitations in certain flares. |
| HBV DNA | Measures active viral replication; informs treatment eligibility and monitoring. |
| HBeAg/anti-HBe | Additional information about replication and infection phase in selected patients. |
For example, HBsAg-negative, anti-HBc-negative and anti-HBs-positive often indicates immunity from vaccination; HBsAg-negative with both anti-HBc and anti-HBs positive suggests past resolved infection. HBsAg-positive warrants additional evaluation rather than an immediate conclusion that the patient needs lifelong therapy [2,6].
Chronic HBV is commonly defined by HBsAg persistence for at least six months. People with past HBV infection can still face reactivation risk during certain immunosuppressive treatments, even if HBsAg becomes negative.
How is hepatitis C diagnosed?
HCV testing generally begins with an anti-HCV antibody test. If positive, perform HCV RNA testing, preferably as reflex testing from the original sample, to determine whether there is current active infection [3,5].
Anti-HCV antibody positive with HCV RNA negative usually indicates no current viremia, potentially from past spontaneous clearance or successful treatment; antibodies often remain positive after cure. Recent exposure can require RNA testing even when antibody is still negative, because seroconversion takes time. A positive antibody test alone should not be labeled chronic active hepatitis C.
How is liver damage assessed?
Evaluation may include ALT, AST, bilirubin, albumin, platelet count, INR, kidney function, viral load, hepatitis coinfections and fibrosis testing. FIB-4, transient elastography or other noninvasive measures can help estimate advanced fibrosis. Ultrasound and additional evaluation may be required when cirrhosis or another complication is suspected.
People with cirrhosis need continued management even if their HCV infection is cured. This may include liver-cancer surveillance and assessment for portal-hypertension complications. A normal ALT alone does not exclude advanced fibrosis [4,5].
HBV treatment: long-term viral suppression
In chronic HBV requiring treatment, commonly preferred oral medicines include tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) and entecavir, selected according to local guideline, age, pregnancy, kidney/bone status, prior treatment and access [1,4]. They inhibit viral reverse transcription/polymerase activity and can lower HBV DNA, reduce inflammation and decrease progression to cirrhosis or liver cancer.
HBV therapy is not required for every HBsAg-positive individual. Eligibility is based on factors such as fibrosis or cirrhosis, HBV DNA, ALT, age, coinfections, pregnancy and specific clinical risks. The 2024 WHO guidance expanded and simplified treatment eligibility, including for some adolescents, while the 2025 AASLD/IDSA update further refined management of specific populations [1,4].
Antiviral treatment often continues for years or indefinitely. Some patients achieve HBsAg loss (functional cure), but HBV cccDNA and other reservoirs make routine complete eradication difficult. Do not abruptly stop HBV antivirals; severe hepatitis flares can follow withdrawal, especially in higher-risk patients.
What about hepatitis B during pregnancy?
All pregnant people should be screened for HBsAg during each pregnancy according to CDC guidance. An infected pregnant person requires assessment of HBV DNA and coordinated maternal/infant preventive care [2,6].
The WHO 2024 HBV guideline supports maternal tenofovir prophylaxis for eligible pregnancies with substantial transmission risk, alongside timely infant HBV vaccination. For infants born to HBsAg-positive mothers, many national protocols recommend hepatitis B vaccine and hepatitis B immune globulin (HBIG) promptly after birth, typically within 12 hours in the United States, followed by completion of the series and postvaccination testing [1,6].
Prevention protocols depend on local resources and guidelines, but maternal treatment does not replace infant immunization. Newborn care should be arranged before delivery whenever possible.
Hepatitis B vaccination and post-exposure prevention
HBV vaccination is the most important specific prevention measure. WHO recommends a timely birth dose followed by a complete vaccine schedule, while CDC has additional age- and risk-based guidance for adults [1,6]. People with household or sexual exposure should be assessed for vaccination and, in selected recent exposures, HBIG and post-exposure prophylaxis according to clinical protocols.
There is no vaccine for HCV. People living with HCV who are not immune should generally be offered hepatitis A and B vaccination where indicated, reducing the risk of additional viral liver injury [3,5].
HCV treatment: modern direct-acting antivirals
Direct-acting antiviral (DAA) medicines target HCV proteins essential for replication, including the NS3/4A protease, NS5A replication complex and NS5B polymerase. Modern pangenotypic combinations are orally administered and often cure more than 95% of treated patients [3,5].
For eligible, previously untreated adults without cirrhosis, AASLD/IDSA simplified treatment pathways commonly recommend:
| Regimen | Typical duration | Important restrictions |
|---|---|---|
| Glecaprevir/pibrentasvir | 8 weeks in suitable treatment-naive patients. | Take with food; protease-inhibitor-containing regimens are not appropriate in decompensated cirrhosis. |
| Sofosbuvir/velpatasvir | 12 weeks for many eligible patients. | Review interactions, including some acid-suppressing medicines; eligibility and regimen differ with cirrhosis, genotype and other factors. |
These are not prescriptions. People with prior treatment failure, decompensated cirrhosis, organ transplantation, pregnancy, certain coinfections or complex drug interactions may require specialist selection and different regimens. Older interferon/ribavirin regimens are no longer standard first-line therapy for uncomplicated HCV in contemporary practice [3,5].
What does “hepatitis C cured” mean?
The standard virologic endpoint is sustained virologic response at least 12 weeks after treatment completion (SVR12), meaning HCV RNA remains undetectable. SVR12 is accepted as a virologic cure for most patients, but it does not create immunity. Reinfection remains possible after new exposure to infected blood [5].
Patients with cirrhosis still require long-term monitoring and hepatocellular carcinoma surveillance because cancer risk falls but does not become zero after cure. Individuals with ongoing exposure risk may need periodic HCV RNA testing rather than relying on antibody tests, which often remain positive.
Drug interactions and hepatitis B reactivation during HCV treatment
Before starting HCV DAAs, assess all prescription and nonprescription medicines, supplements, liver function, renal function, HIV status and HBV infection markers. Interactions occur with some anticonvulsants, rifamycins, acid reducers, statins and other agents; the exact issue depends on the antiviral combination [3,5].
HBV reactivation can occur during or after HCV DAA therapy in some people with current or previous HBV infection. AASLD/IDSA guidance requires HBV assessment and appropriate monitoring or HBV treatment according to risk. Do not start antivirals without a complete medication and coinfection review.
Hepatitis D and HIV coinfection
Hepatitis D virus (HDV) requires HBV surface antigen to infect cells; people with chronic HBV may need HDV antibody testing and further RNA testing under modern guidance, especially in higher-prevalence settings [1]. HIV coinfection changes antiviral regimen decisions, potential interactions and monitoring, but should not be used as a reason to deny effective HBV or HCV care.
Reducing transmission and protecting the liver
- Get vaccinated for HBV and complete the recommended series.
- Never share needles, syringes, injection equipment, razors or toothbrushes that may contain blood.
- Use appropriate infection-control and sterile procedures in healthcare, piercing and tattooing.
- Discuss condom use and partner testing when sexual exposure risk is relevant.
- Limit or avoid alcohol, especially with chronic liver disease, and review hepatotoxic medicines.
- Seek evaluation of fibrosis, cirrhosis and liver-cancer surveillance needs.
- Encourage testing and linkage to care without blame or discrimination.
Frequently asked questions
Can someone have chronic HBV or HCV without symptoms?
Yes. Many chronic infections are silent for years, making testing and follow-up important [2,3].
Is there a vaccine for hepatitis C?
No. HCV can usually be cured with direct-acting antivirals, but an effective preventive vaccine is not available [3].
Does a positive anti-HCV test prove current infection?
No. HCV RNA testing is needed to establish current viremia.
Are hepatitis B medicines a permanent cure?
Usually not. They suppress viral replication and reduce complications; long-term treatment is often needed [1,4].
How long does modern hepatitis C treatment take?
Often 8–12 weeks for eligible patients, but complex cases require a tailored plan [5].
Does curing HCV eliminate all liver-cancer risk?
No. People with cirrhosis still need appropriate surveillance.
Key takeaways
HBV and HCV require different prevention and treatment strategies. Hepatitis B is vaccine-preventable and often managed with long-term antivirals; hepatitis C has no vaccine but can usually be cured with short-course DAAs. Correct serology, RNA testing, fibrosis assessment, drug-interaction review and cancer surveillance are central to evidence-based care.
References
- World Health Organization. Guidelines for prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. WHO; 2024.
- Centers for Disease Control and Prevention. Clinical testing and diagnosis for hepatitis B. CDC; accessed 8 Nov 2026.
- World Health Organization. Hepatitis C: fact sheet. Updated 28 Jul 2026.
- Ghany MG, et al. AASLD/IDSA practice guideline update on treatment of chronic hepatitis B. Hepatology. 2025. doi:10.1097/HEP.0000000000001549.
- American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: simplified treatment for treatment-naive adults without cirrhosis. Updated 2026.
- Centers for Disease Control and Prevention. Clinical overview of hepatitis B and perinatal prevention. CDC.
Medical disclaimer: Educational material only. Hepatitis test results and antiviral eligibility require qualified interpretation. Do not start or stop antiviral medicines without medical supervision. Severe jaundice, confusion, bleeding or other signs of liver failure require urgent care.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.